RBC Capital Remains a Hold on SAGE Therapeutics (SAGE)
RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...
Seeking Alpha3d
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...
EconoTimes3d
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...
Business Insider3d
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...
Yahoo Finance3d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... result in any transaction or other strategic outcome. Sage does not intend to disclose further developments on this strategic ...
Nasdaq3d
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE ... opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s ...
Investing3d
Sage Therapeutics shares rise amid strategic review
Investing.com -- Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...
Yahoo Finance4d
Sage rejects Biogen's $469 million takeover offer
(Reuters) -Sage ... does not already own for $7.22 apiece, "significantly undervalues Sage and believes it is not in the best interest of shareholders." Biogen has a 10.2% stake in Sage Therapeutics.
Yahoo Finance3d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... strategic review process will result in any transaction or other strategic outcome. Sage does not intend to disclose further ...
Morningstar3d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression Sage Therapeutics ... Sage does not intend to disclose further ...
pharmaphorum3d
Sage rejects Biogen takeover and launches review
The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...
Investing3d
Sage Therapeutics shares rise amid strategic review
Investing.com -- Sage (LON:SGE) Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and ...